Researchers performed a systematic review and meta-analysis to summarize and update the evidence regarding the effects of lifestyle intervention, including diet, on cardiometabolic risk among overweight and obese women with PCOS.
The study authors theorized that the interplay between inflammation and cytokines may influence mood and behavioral disturbances, which could explain the overlap between PCOS and bipolar disorder.
Symptoms of PCOS typically manifest during the early pubertal years, though diagnosing this condition in adolescence remains a clinical challenge.
Findings show that anti-Müllerian hormone (AMH) is a strong predictor for menstrual disturbance due to PCOS and that the risk for menstrual disturbance was increased with the degree of elevation of AMH.
In a cohort of premenopausal women with PCOS, metformin treatment for 3 months was associated with reduced bone turnover.
Letrozole treatment may significantly improve live birth rate compared with artificial-cycle frozen embryo transfer in women with polycystic ovary syndrome.
Researchers identified rare genetic variants in the DENND1A gene that may contribute to the distinctive hormonal traits of polycystic ovary syndrome.
In pregnant women with polycystic ovary syndrome (PCOS), metformin treatment from the late first trimester until delivery might reduce the risk for late miscarriage and preterm birth but does not prevent gestational diabetes.
Irrespective of age and weight, women with polycystic ovary syndrome have an increased risk for type 2 diabetes.
Researchers observed that sleep disturbances may be more prevalent in women with polycystic ovary syndrome.
